Home Featured

Featured

Random

Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.

Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and...

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

AIMS v. DEA: Advocating for Open Access to Psilocybin Assisted Therapy

MINDCURE Announces Financial Results for Fiscal 2021

PTSF83 – Abuse in Psychedelics: Complicity and Groupthink

Mindset Pharma Files National Patents Protecting Family 1 Application in 16...

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics...

Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing...

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use...

Bright Minds Announces Proposed Share Consolidation

12 3...300 Page 1 of 300

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants...

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.